Dataset Information


Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.

ABSTRACT: Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response. Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors. Numerous clinical trials are ongoing or completed, including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer. This review considers the molecular mechanisms associated with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer.


PROVIDER: S-EPMC4125367 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5517319 | BioStudies
2018-01-01 | S-EPMC6026053 | BioStudies
2012-01-01 | S-EPMC3501233 | BioStudies
2018-01-01 | S-EPMC6095972 | BioStudies
2013-01-01 | S-EPMC3835685 | BioStudies
2011-01-01 | S-EPMC3157979 | BioStudies
2014-01-01 | S-EPMC4000187 | BioStudies
2020-01-01 | S-EPMC7137211 | BioStudies
2019-01-01 | S-EPMC6825570 | BioStudies
1000-01-01 | S-EPMC4342830 | BioStudies